A phase II study of dacarbazine, cisplatin, interferon-α and high-dose interleukin-2 in ‘poor-risk’ metastatic melanoma
- 31 August 1996
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 32 (9) , 1530-1533
- https://doi.org/10.1016/0959-8049(96)00135-9
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Addition of dacarbazine or cisplatin to interferon-??/interleukin-2 in metastatic melanomaMelanoma Research, 1995
- Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastasesPublished by Elsevier ,1994
- Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinomaCancer, 1994
- Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.Journal of Clinical Oncology, 1993
- Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trialsCancer, 1993
- Interleukin-2 therapy for metastatic uveal melanomaEuropean Journal Of Cancer, 1992
- Sequential chemoimmunotherapy in the treatment of metastatic melanoma.Journal of Clinical Oncology, 1992
- Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.Journal of Clinical Oncology, 1989
- The Neuropsychiatric Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987